Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

Table 1

Patient characteristics.

Patient	Diagnosis; (fusion protein/cytogenetic finding)	Age	Age at FD	Sex	Number of prior chemoregimens	Prior radiation therapy	Total number of cycles received	Maximum toxicities	Best response
(1)	Ewing sarcoma (second malignancy, initially fibrosarcoma)	21	4	m	7	Yes	1	Leukopenia G3	SD, DOD
(2)	Alveolar rhabdomyosarcoma; (PAX3-FKHR/t(2;13)(q35;q14))	17	13	m	3	Yes	2	Leukopenia G4, thrombocytopenia G4, hepatic G4, pancreatitis G3, infection G3	PD, DOD
(3)	Synovial sarcoma; (SYT-SSX2/t(X;18))	18	8	m	2	No	7	Pancytopenia G4, hepatic G4, infection G3	PR, DOD
(4)	Ewing sarcoma; (EWS-FLI1/t(11;22)(q24;q12))	18	13	f	2	Yes	2	Hepatic G3	PD, DOD
(5)	Ewing sarcoma; (EWS-FLI1/t(11;22)(q24;q12))	43	11	m	3	Yes	11	Hepatic G3	SD, DOOC
(6)	Ewing sarcoma; (EWS-FLI1/t(11;22)(q24;q12))	28	22	m	2	Yes	3^+	Diarrhea G4, pancytopenia G4, infection G4	SD
(7)	Ewing sarcoma; (EWSR1-FLI1/t(11;22)(q24;q12); type II (EWSR1-Exon7/FLI1-Exon5))	35	16	m	6	Yes	2	Leukopenia G4, mucositis G3, hepatic G3	PD, DOD
(8)	Ewing sarcoma; (EWSR1-FLI1/t(11;22)(q24;q12))	60	57	f	5	Yes	3	Pancytopenia G4, FUO in Neutropenia G4	SD, DOD
(9)	Ewing sarcoma; (EWSR1-FLI1/t(11;22)(q24;q12))	24	20	f	6	Yes	3	FUO in neutropenia G4, mucositis G3, diarrhea G3	SD, DOD
(10)	Ewing sarcoma; (EWSR1-FLI1/t(11;22)(q24;q1); EWSR1-Exon 7/FLI1-Exon 6; type I))	24	14	m	6	Yes	2	No toxicity	PD, DOD
(11)	Desmoplastic small round cell tumor; (EWSR1-WT1/t(11;22)(p13;q12))	12	6	m	3	Yes	6	Pancytopenia G4, hepatic G4	PD, DOD
(12)	Alveolar rhabdomyosarcoma; (PAX3-FKHR/t(2;13)(q35;q14))	17	15	f	2	Yes	5	Pancytopenia G4, hepatic G3	PD, DOD

(a) FD: first diagnosis; (b) while histological diagnosis of the patient’s second malignancy was Ewing sarcoma, the EWSR1-FLI1 translocation could neither be confirmed nor ruled out conclusively; (c) SD: stable disease; (d) DOD: death of disease; (e) PD: progressive disease; (f) PR: partial remission (continued therapy until PD and DOD); (g) DOOC: death of other causes; (h) prior exposure to irinotecan. (+) indicates that the patient is still on therapy; Pt. no. 6 continued with trabectedin as a single agent.